Valeant Targets Cesamet On Breast Cancer As It Waits For Pain Claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While a chemotherapy-induced neuropathic pain indication is in development, Valeant is relaunching the synthetic cannabinoid Cesamet with a new strategy for its approved antiemetic use that will focus on physicians treating breast cancer at high-volume teaching institutions, President-Valeant North America/R&D Wesley Wheeler told a May 1 earnings call
You may also be interested in...
Valeant taps Parexel to shepherd retigabine regulatory filings
Valeant's planned mid-2008 NDA and MAA submissions for the anti-epileptic retigabine will be managed by Parexel. The contract services organization will "develop, coordinate and prepare" the NDA as well as the European MAA, Valeant says. Retigabine, a neuronal potassium-channel opener, is being studied in two international Phase III studies - RESTORE1 and RESTORE2 - as an adjunct treatment for partial onset seizures in patients with refractory epilepsy. Pharmaceutical Approvals Monthly erred in identifying the Phase III program in a previous story (1Pharmaceutical Approvals Monthly May 2007, p. 7). Valeant announced the initiation of a Phase IIa study of retigabine treatment of pain associated with post-herpetic neuralgia on May 31; the proof-of-concept study will enroll 180 patients...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.